ClinicalTrials.gg
CompletedNCT03350165Updated Apr 9, 2021

A Study of Pemafibrate in Patients With Nonalcoholic Fatty Liver Disease (NAFLD)

A Phase 2 interventional study of K-877 and Placebo in Non-Alcoholic Fatty Liver Disease, sponsored by Kowa Company, Ltd.. Completed at 16 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2021-04-09.

Sponsored by Kowa Company, Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
118
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 38 studies in Non-alcoholic Fatty Liver Disease with a site in Japan — 5 open to participants now, 9 under way, 6 of them phase 3. Non-alcoholic Fatty Liver Disease · Japan.

Enrollment
27th of 37
118 · median 220
Started
2017
with 3 others
Phase 2
23 of 38
none open now
Registered
7th of 38
by date

Among the 38 studies in Non-alcoholic Fatty Liver Disease with a site in Japan, this one is the 27th largest by enrollment of the 37 interventional ones that give a count, is one of 4 that started in 2017, is one of 23 in phase 2, and was the 7th registered.

Non-alcoholic Fatty Liver Disease

1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

5 of the 38 studies in Non-alcoholic Fatty Liver Disease with a site in Japan are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Non-alcoholic Fatty Liver Disease with a site in Japan, or all of them as a file.
02

Study summary

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Pemafibrate in Patients With Nonalcoholic Fatty Liver Disease.

03

Conditions studied

  • Non-Alcoholic Fatty Liver Disease
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients show presence of hepatic fat fraction as defined by ≥ 10% on MRI-PDFF at Screening
  2. Patients show presence of liver stiffness as defined by ≥ 2.5 kPa on MRE at Screening
  3. Patients have an above the (30 IU/L for females and 40 IU/L for males) at Screening
  4. Patients with NAFLD had to be age 20 years or older at written (ICF)

Exclusion criteria

Exclusion Criteria:

  1. Current of significant alcohol consumption (significant alcohol consumption is defined as more than 210 g/week in males and more than 140 g/week in females, on average)
  2. Planned use of Medications from written ICF to end of treatment.
  3. \< 22 kg/m2 at Screening
  4. Uncontrolled diabetes mellitus as defined by a (NGSP) ≥ 8.0% at Screening
  5. \< 30 mL/min/1.73m2 or Dialysis patient
  6. Cirrhosis
  7. Biliary obstruction
  8. Patients were excluded if they had evidence of other forms of liver disease shown by the following:

    • or
    • hepatitis(AIH)
    • Primary biliary cirrhosis(PBC)
    • Primary Sclerosing Cholangitis(PSC)
    • Drug-induced liver injury
    • hyperthyroidism, Wilson's disease, hemochromatosis, alpha-1-antitrypsin disease
  9. Those with complicating malignant neoplasm or those judged to be at a high risk of recurrence
  10. Patients with contraindications to MRI imaging
  11. Patients who gave 200 mL or more of blood within 1 month before the administration of the study drug, or 400 mL or more of blood within 4 months before the administration of the study drug
  12. Patients with a history of serious drug allergies (such as anaphylactic shock)
  13. Pregnancy, breast feeding, planned pregnancy
  14. Patients who were participating in another clinical study at the time of consent was obtained or who received study drugs other than the placebo less than 16 weeks before consent was obtained
  15. Patients who have previously been administered pemafibrate
  16. Patients who have been determined inappropriate by the investigator or subinvestigator
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
118 participants (actual)

Study arms

  • Experimental
    Treatment Group

    K-877 (pemafibrate) tablet twice daily.

    Drug: K-877

  • Placebo comparator
    Control Group

    placebo tablet twice daily.

    Drug: Placebo

Interventions

  • DrugK-877

    0.2mg tablet

    Also known as: pemafibrate

  • DrugPlacebo

    K-877 matching placebo tablet

06

What researchers measure

Primary outcomes

  1. Efficacy: % Change from baseline to Week 24 in hepatic fat fraction by Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF)

    Time frame: Week 24

  2. Safety: Incidence of adverse events and adverse drug reactions that occurred after the administration of the study drug

    Time frame: Week 24

Secondary outcomes

  1. Change in noninvasive imaging biomarkers (MRI-PDFF in %, MRE in kPa, Transient elastography in kPa)

    Time frame: From baseline upto week 72

  2. Change in clinical laboratory tests (AST in IU/L, ALT in IU/L, γ-GTP in IU/L)

    Time frame: From baseline upto week 72

  3. Change in noninvasive biomarkers (Cytokeratin 18 in U/L, Hyaluronic acid in ng/mL, Type IV collagen 7S in ng/mL, M2BPGi in no unit)

    Time frame: From baseline upto week 72

  4. Change in noninvasive biomarkers (NAFLD fibrosis score)

    Time frame: From baseline upto week 72

  5. Change in noninvasive biomarkers (FIB4 index)

    Time frame: From baseline upto week 72

  6. Change in noninvasive biomarkers (NAFIC score)

    Time frame: From baseline upto week 72

  7. Change in noninvasive biomarkers (ELF test)

    Time frame: From baseline upto week 72

  8. Percentage of patients with ≥ 30% reduction in hepatic fat fraction (MRI-PDFF)

    Time frame: From baseline upto week 72

  9. Percentage of patients with ≥ 15% reduction in liver stiffness (MRE)

    Time frame: From baseline upto week 72

07

Study locations

16 sites
  • Aomori Prefectural Central Hospital
    Aomori, Aomori, 030-8553, Japan
  • Asahikawa Medical University
    Asahikawa, Hokkaido, 078-8510, Japan
  • Fukuwa Clinic
    Chuo-ku, Tokyo, 104-0031, Japan
  • Fukuoka University Hospital
    Fukuoka, Fukuoka, 814-0180, Japan
  • SeireiHamamatsu General Hospital
    Hamamatsu, Shizuoka, 430-8558, Japan
  • Hamamatsu University Hospital
    Hamamatsu, Shizuoka, 431-3192, Japan
  • Iwata City Hospital
    Iwata, Shizuoka, 438-8550, Japan
  • Chutoen General Medical Center
    Kakegawa, Shizuoka, 436-8555, Japan
  • Kurume University Hospital
    Kurume, Fukuoka, 830-0011, Japan
  • Niigata University Medical & Dental Hospital
    Niigata, Niigata, 951-8520, Japan
  • Ogaki Municipal Hospital
    Ogaki, Gifu, 503-8502, Japan
  • Shiga University of Medical Science Hospital
    Otsu, Shiga, 520-2192, Japan
  • Hokkaido University Hospital
    Sapporo, Hokkaido, 060-8648, Japan
  • Yamagata University Hospital
    Yamagata, Yamagata, 990-9585, Japan
  • Saiseikai Yokohamashi Tobu Hospital
    Yokohama, Kanagawa, 230-8765, Japan
  • Yokohama City University Hospital
    Yokohama, Kanagawa, 236-0004, Japan
08

References and documents

Publications

  • Nakajima A, Eguchi Y, Yoneda M, Imajo K, Tamaki N, Suganami H, Nojima T, Tanigawa R, Iizuka M, Iida Y, Loomba R. Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator (SPPARMalpha), versus placebo in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2021 Nov;54(10):1263-1277. doi: 10.1111/apt.16596. Epub 2021 Sep 16. PubMed 34528723 ↗
  • Fruchart JC, Hermans MP, Fruchart-Najib J, Kodama T. Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARMalpha) in the Metabolic Syndrome: Is Pemafibrate Light at the End of the Tunnel? Curr Atheroscler Rep. 2021 Jan 3;23(1):3. doi: 10.1007/s11883-020-00897-x. PubMed 33392801 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2017 to primary completion in Apr 2019, 15 months.

Of 132 industry-sponsored phase 2 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 15 months is below that.

Counting every sponsor, half of 185 studies reached it within 26 months; a quarter within 16 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2017
First posted
Nov 22, 2017
StartActual
Dec 27, 2017
Primary completionActual
Apr 3, 2019
CompletionActual
Jun 30, 2020
Last update
Apr 9, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03350165
Lead sponsor
Kowa Company, Ltd.
Responsible party
Sponsor
First posted
Nov 22, 2017
Start date
Dec 27, 2017
Primary completion
Apr 3, 2019
Completion
Jun 30, 2020
Last update
Apr 9, 2021

Study contacts

Ryohei Tanigawa
study director · Clinical Development Dept. Ⅰ

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pemafibrate

Start the discussion